Business Context and Reporting Period
This Form 8-K Current Report was filed by TriSalus Life Sciences, Inc. on April 7, 2026, covering events occurring on April 1, 2026. The filing primarily addresses the appointment of a new executive officer and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figures disclosed relate to executive compensation:
- Annual Base Salary: $525,000
- Sign-on Bonus: $250,000
- Annual Bonus Potential: Up to 50% of base salary
- Equity Grant Recommendation: 120,000 stock options and 60,000 restricted stock units
Material Changes
The material change reported is the appointment of Dr. Richard Marshall as the new Chief Medical Officer. His employment is scheduled to commence on June 29, 2026. No other material changes to operations, financial condition, or corporate structure are disclosed in this report.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. The document notes that the equity award is subject to Board approval and that the annual bonus is contingent upon the achievement of financial goals and milestones determined by the Board.
Investor Verification Checklist
- Verify the start date of Dr. Marshall's employment (June 29, 2026) against the company's operational timeline.
- Confirm the final Board approval of the recommended equity award (120,000 options and 60,000 RSUs).
- Review the specific financial goals and milestones required to trigger the variable annual bonus.
- Check for any subsequent filings regarding the impact of this appointment on the company's cash burn or capitalization.